Quantitative CHEK2 Antibody Applications in Cell Cycle Checkpoint Studies

Posted on by Sarah

Biological context: why quantify CHEK2?

Checkpoint kinase 2 (CHEK2) is a serine/threonine kinase activated primarily downstream of ATM following DNA double-strand breaks. Autophosphorylation at Thr68 enables trans-autophosphorylation and substrate engagement, propagating arrest via substrates including TP53, BRCA1, and CDC25C to coordinate G1/S, intra-S, and G2/M checkpoints. Concise reference entries: NCBI Gene—CHEK2, NCI dictionary: CHEK2, NIGMS cell-cycle overview, and NIEHS DNA repair. For pathway neighbors: ATM, TP53, BRCA1, CDC25C. Clinical and variant context: MedlinePlus Genetics—CHEK2, ClinVar CHEK2, dbSNP CHEK2.

Quantitative readouts—especially phospho-CHEK2 (Thr68) relative to total CHEK2—provide a pharmacodynamic and mechanistic window into DNA damage response (DDR) integrity and drug effects.

AffiAB® CHEK2 Antibody

Antibody selection and validation for quantitation

For robust quantitation, combine:

  • Phospho-specific anti-CHEK2 (pThr68) to measure activation.

  • Total CHEK2 antibody to normalize expression.

  • Downstream markers (e.g., p53 Ser15, BRCA1 Ser/Thr sites, CDC25C Ser216) to triangulate checkpoint engagement.

Follow rigorous validation practices and reproducibility guidance from NIH Rigor & Reproducibility. Where possible, leverage community resources like the NCI Antibody Characterization Program (antibodies.cancer.gov) for orthogonal characterization. For consistent data processing pipelines, consult PubMed/PMC for target-specific validations and protocols.

Quantitative western blot (WB) for CHEK2 signaling

Goal: Determine pCHEK2(Thr68)/total CHEK2 ratios over a linear detection range.

Key steps:

  1. Sample preservation: Include protease/phosphatase inhibitors; verify lysis compatibility with downstream antibodies (NIH guidance on rigor: link).

  2. Dynamic range and linearity: Titrate total protein (e.g., 5–40 µg) to stay within ECL linear range; prefer total-protein normalization or validated housekeeping controls.

  3. Calibrators & standards: Where feasible, spike recombinant CHEK2 to build semi-absolute curves; consult NIST materials and metrology concepts (NIST proteomics standards, NIST Engineering Statistics Handbook).

  4. Curve fitting & reporting: Use 4-parameter logistic (4PL) or linear fits as appropriate; specify LoB/LoD/LoQ following FDA bioanalytical method validation principles (FDA guidance).

  5. Controls: Include vehicle control, DNA-damage positive control (e.g., ionizing radiation or radiomimetic dosing), and pathway-inhibition controls (e.g., ATM inhibition) to test dependency.

QC notes: Report exposure times, antibody lots, membrane type, and replicate structure; archive raw 16-bit TIFFs and analysis steps (NIH rigor link above).

Image générée

Sandwich ELISA / ECL immunoassays

Use case: Higher-throughput quantitation of pCHEK2(Thr68) and total CHEK2.

  • Capture/Detection pairing: Capture total CHEK2; detect with phospho-specific antibody, or run separate assays (pCHEK2 and total CHEK2) to compute ratios.

  • Standardization: Build standard curves with recombinant antigen; fit 4PL; declare backfit residuals, precision (intra/inter-assay), and matrix effects (per FDA guidance).

  • Traceability: Describe calibrator source and any linkage to NIST reference materials or internal references (NIST programs).

Phospho-flow cytometry (single-cell pCHEK2)

Objective: Quantify pCHEK2(Thr68) at single-cell resolution across the cell cycle.

  • Fix/perm optimization: Methanol or dedicated phospho-flow buffers; benchmark with core-tested protocols (e.g., UC Davis Flow Cytometry Core: health.ucdavis.edu/flowcytometry; Stanford/Med: med.stanford.edu).

  • Cell-cycle stratification: Add DNA dyes (e.g., DAPI) to gate G1/S/G2-M; co-stain checkpoint markers to map pathway spread.

  • Compensation/controls: FMO and isotype controls; bead-based instrument QC.

  • Reporting standard: Align to MIFlowCyt best practices via PubMed resources (MIFlowCyt on PubMed).

Quantitative immunofluorescence & high-content imaging (HCI/HCS)

Applications: Spatial mapping of pCHEK2 foci; multiplex with γH2AX and 53BP1; compute per-nucleus intensity and foci counts.

  • Platform & core references: UT Southwestern High-Throughput Screening Core (utsouthwestern.edu) and other academic HCS cores often provide exposure-linearity and segmentation guidance.

  • Assay quality: Report Z′-factor for dynamic range and separation; the metric is widely cited in the screening literature (see PubMed overview: Z′-factor).

  • Analysis: Normalize per-plate using robust statistics; export per-cell data and provide gate/threshold definitions.

Immunoprecipitation-mass spectrometry (IP-MS) for CHEK2 networks

Immunoenrich CHEK2 and quantify co-precipitating substrates/complexes to infer pathway activity. Cross-validate with orthogonal readouts (WB, phospho-flow). Proteomic metrology and calibration concepts are covered by NIST (proteomics standards). Academic proteomics cores provide SOPs and QA frameworks (e.g., Yale Keck MS & Proteomics: medicine.yale.edu/keck/proteomics).

Experimental design for cell-cycle checkpoint studies

  1. Model selection: Choose cells with intact DDR or defined deficiencies; document CHEK2 genotype/variants (ClinVar CHEK2; dbSNP CHEK2).

  2. Perturbations: Apply DNA damage (e.g., IR, topoisomerase poisons). Include rescue (e.g., ATM dependency via inhibitor washout) to test pathway wiring (NCBI Gene ATM).

  3. Multi-endpoint quantitation: Combine WB, ELISA/ECL, phospho-flow, and HCI to triangulate pCHEK2 kinetics, cell-cycle phase effects, and downstream signaling (TP53, BRCA1, CDC25C).

  4. Statistics: Predefine primary endpoints (e.g., pCHEK2/total CHEK2 ratio), replicates (≥3 biological), and analysis plan. Use the NIST Engineering Statistics Handbook for power, ANOVA, and linearity checks (NIST handbook).

Data processing, normalization, and reporting

  • Normalization choices:

    • WB: total-protein normalization or stable housekeeping; verify invariance under treatment (NIH rigor: link).

    • ELISA/ECL: 4PL curve; report %CV, back-calculated concentrations, and dilutional linearity (per FDA: bioanalytical validation).

    • Flow/HCI: per-cell intensity normalization; batch correction with control wells/controls cores (see UTSW HCS core: utsouthwestern.edu).

  • Image quantification: Provide ImageJ macro or pipeline details; ImageJ resource hub: imagej.nih.gov/ij.

  • Sequence/epitope context: Retrieve CHEK2 protein regions for epitope mapping via NCBI Protein (CHEK2 query) and controlled vocabularies via MeSH Browser (MeSH).

Image générée

Controls, pitfalls, and troubleshooting

  • Specificity controls: CRISPR/Cas9 knockout or siRNA depletion of CHEK2; pathway inhibition upstream (ATM) or parallel (CHEK1) to test selectivity (see NCBI Gene ATM).

  • Cross-reactivity: Confirm phospho-site specificity by peptide competition.

  • Pre-analytical variables: Cell cycle synchronization can skew baseline pCHEK2; document synchronization method.

  • Documentation: Follow reproducible reporting checklists (NIH rigor: link); include reagent lots, catalog/clone IDs, and raw data availability (deposit figures/tables; literature tracking via PubMed/PMC).

Example quantitative endpoints to report

  • Primary: pCHEK2(Thr68)/total CHEK2 ratio vs time/dose.

  • Secondary: p53(Ser15) induction; CDC25C(Ser216) phosphorylation; fraction of γH2AX-positive nuclei.

  • Single-cell metrics: Median fluorescence intensity (MFI) shifts for pCHEK2 by cell-cycle phase (phospho-flow), foci counts per nucleus (HCI).

  • Assay quality: Z′-factor per plate or run (Z′-factor on PubMed).

Leave a Reply

Your email address will not be published.